Yiwei Tong
YOU?
Author Swipe
View article: Development and validation of prognostic model based on distribution and density of CD3+ and CD8+ infiltrating lymphocytes in breast cancer: A multicenter cohort study
Development and validation of prognostic model based on distribution and density of CD3+ and CD8+ infiltrating lymphocytes in breast cancer: A multicenter cohort study Open
View article: SatFusion: A Unified Framework for Enhancing Satellite IoT Images via Multi-Temporal and Multi-Source Data Fusion
SatFusion: A Unified Framework for Enhancing Satellite IoT Images via Multi-Temporal and Multi-Source Data Fusion Open
With the rapid advancement of the digital society, the proliferation of satellites in the Satellite Internet of Things (Sat-IoT) has led to the continuous accumulation of large-scale multi-temporal and multi-source images across diverse ap…
View article: Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer
Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer Open
Aim: Resistance to trastuzumab remains a major barrier to cure in early-stage HER2-positive breast cancer (HER2+ BC). We investigated the impact of genomic alterations and tumor-infiltrating lymphocyte (TIL) density on treatment resistance…
View article: Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer
Dihydroartemisinin targets the miR-497-5p/SOX5 axis to suppress tumor progression in non-small cell lung cancer Open
Introduction Non-small cell lung cancer (NSCLC) remains a lethal malignancy with limited therapeutic options. Although dihydroartemisinin (DHA) exhibits anticancer properties, its mechanisms in NSCLC are incompletely understood. This study…
View article: Clinicopathological and molecular significance of HER2-low expression in Asian women with triple-negative breast cancer
Clinicopathological and molecular significance of HER2-low expression in Asian women with triple-negative breast cancer Open
Background: Heterogeneity of human epidermal growth factor receptor 2 (HER2) expression exists in triple-negative breast cancer (TNBC). The evolution of the HER2 testing algorithm has led to the new classification of the HER2-low category,…
View article: Development and Validation of Prognostic Model Based on Distribution and Density of Cd3+ and Cd8+ Infiltrating Lymphocytes in Breast Cancer: A Multicenter Cohort Study
Development and Validation of Prognostic Model Based on Distribution and Density of Cd3+ and Cd8+ Infiltrating Lymphocytes in Breast Cancer: A Multicenter Cohort Study Open
View article: Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer
Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer Open
View article: Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model
Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model Open
Objectives Anti-HER2 targeted therapy significantly reduces risk of relapse in HER2 + breast cancer. New measures are needed for a precise risk stratification to guide (de-)escalation of anti-HER2 strategy. Methods A total of 726 HER2 + ca…
View article: Unveiling miRNA30b’s Role in Suppressing ADAM12 to Combat Triple‐Negative Breast Cancer
Unveiling miRNA30b’s Role in Suppressing ADAM12 to Combat Triple‐Negative Breast Cancer Open
Background: Triple‐negative breast cancer, a subtype of breast cancer, is characterized by a poor prognosis. Recent studies have shown that miRNA30b acts as an oncogene and is vital for the proliferation of malignancies across various syst…
View article: 408P Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study
408P Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study Open
View article: Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in <scp>HER2‐low</scp> breast cancer: A comparison study with <scp>HER2</scp>‐zero and <scp>HER2</scp>‐positive disease
Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in <span>HER2‐low</span> breast cancer: A comparison study with <span>HER2</span>‐zero and <span>HER2</span>‐positive disease Open
Introduction HER2‐low breast cancer is a gradually recognized and unexplored group of diseases. We aimed to investigate the clinical and prognosis features and to identify the role of stromal tumor‐infiltrating lymphocytes (sTILs) in this …
View article: Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer Open
Background Characterizing the unique immune microenvironment of each tumor is of great importance for better predicting prognosis and guiding cancer immunotherapy. However, the unique features of the immune microenvironment of triple negat…
View article: Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients Open
Ki67 would change after core needle biopsy (CNB) in invasive breast cancer. However, whether Ki67 alteration (ΔKi67) influences disease outcomes remains unclear. Here we aim to evaluate the prognostic value of ΔKi67. Patients with paired C…
View article: Nodal Underestimation Rate in Early-Stage ER /HER2- Breast Cancer Patients with Limited Positive Sentinel Lymph Nodes in the Era of Precise Medication: A Real-World Multicenter Analysis from 40 Institutions in China
Nodal Underestimation Rate in Early-Stage ER /HER2- Breast Cancer Patients with Limited Positive Sentinel Lymph Nodes in the Era of Precise Medication: A Real-World Multicenter Analysis from 40 Institutions in China Open
View article: Associaction between Prognosis, Carboplatin Treatmene Response and Homologous Recombination Deficiency Status in Early Triple-Negative Breast Cancer
Associaction between Prognosis, Carboplatin Treatmene Response and Homologous Recombination Deficiency Status in Early Triple-Negative Breast Cancer Open
View article: Top Design of Digitalization Specialty in a Power Company Based on TOGAF Framework
Top Design of Digitalization Specialty in a Power Company Based on TOGAF Framework Open
Starting with the concept of top-level design, this paper analyzes and introduces the significance, ideas and contents of top-level design. And taking the digital professional system of an electric power company as an example, according to…
View article: Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients
Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients Open
Introduction Tumor immune microenvironment (TIME) plays a vital role in breast cancer development, treatment resistance, and prognosis. This study evaluates the association of TIME profiling and 21-gene recurrence score (RS) in early Lumin…
View article: HER2-Low Status Is Not Accurate in Breast Cancer Core Needle Biopsy Samples: An Analysis of 5610 Consecutive Patients
HER2-Low Status Is Not Accurate in Breast Cancer Core Needle Biopsy Samples: An Analysis of 5610 Consecutive Patients Open
Background: HER2-Low status is found in approximately half of breast cancer patients and shows potential benefits from novel antibody–drug conjugates (ADCs). Data on the accuracy of HER2-Low status between core needle biopsy (CNB) and surg…
View article: Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial Open
Purpose Breast cancer patients with metabolic syndrome (MetS) and its components show worse treatment responses to chemotherapy. Metformin is a widely used antidiabetic drug which also shows potential anticancer effect. This study aims to …
View article: Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer Open
Background: Human epidermal growth factor receptor 2 (HER2)-low tumor is a new entity defined as HER2 immunohistochemistry (IHC) 1+ or 2+/fluorescence in situ hybridization (FISH)-negative. We aimed to evaluate whether HER2 mRNA levels tes…
View article: Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients
Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients Open
Purpose To evaluate whether changes in ultrasound features during neoadjuvant chemotherapy (NAC) could predict axillary node response in clinically node-positive breast cancer patients. Methods Patients with biopsy-proven node-positive dis…
View article: Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients Open
Purpose To evaluate the influence of obesity on clinicopathological characteristics of breast cancer; to explore the effect of obesity on the prognosis and performance of endocrine therapy in breast cancer patients. Methods Patients with l…
View article: Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer.
Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer. Open
Triple negative breast cancer (TNBC) is a breast cancer subtype with unfavorable prognosis. We aimed to establish a machine learning-based ultrasound radiomics model to predict disease-free survival (DFS) in TNBC. Invasive TNBC>T1b between…
View article: Can HER2-Low Tumor Be Considered as a Biologically Distinct Subtype with HER2-Zero Tumor in Triple-Negative Breast Cancer: Comparison Clinical Characteristics, Gene Mutation Spectrums, Gene Expression Levels, and Prognosis
Can HER2-Low Tumor Be Considered as a Biologically Distinct Subtype with HER2-Zero Tumor in Triple-Negative Breast Cancer: Comparison Clinical Characteristics, Gene Mutation Spectrums, Gene Expression Levels, and Prognosis Open
View article: Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients
Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients Open
Purpose With the application of “less extensive surgery” in breast cancer treatment, the pattern of locoregional recurrence (LRR) has significantly changed. This study aims to evaluate the risk and prognostic factors of LRR in a recent lar…
View article: Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients Open
Purpose Our purpose was to evaluate the influence of obesity on clinicopathological characteristics of breast cancer. Secondly we wanted to explore the effect of obesity on the performance of endocrine therapy in Chinese breast cancer pati…
View article: 21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients Open
Background Comprehensive investigations of the associations between 21-gene recurrence assay and metabolic profiles in Chinese breast cancer patients are limited. Methods We evaluated the relations of the 21-gene recurrence risk score (RS)…
View article: Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis
Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis Open
RS was differently distributed between recurrent and nonrecurrent patients. PR, BCL2, CEGP1, and STMY3 expression was associated with LRR and DM, while CEGP1 was lower in the LRR group than DM patients, w…
View article: Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients
Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients Open
Background Biomarker discrepancy between primary and recurrent/metastatic breast cancer is well known, however its impact on prognosis and treatment after relapse is still unclear. Current study aims to evaluate biomarkers discrepancy betw…
View article: ESA VERSUS MESA WITH SANDWICHED RADIOTHERAPY IN PATIENTS WITH EARLY‐STAGE NATURAL KILLER/T‐CELL LYMPHOMA: A MULTICENTRE, RANDOMISED, PHASE 3, NON‐INFERIORITY TRIAL
ESA VERSUS MESA WITH SANDWICHED RADIOTHERAPY IN PATIENTS WITH EARLY‐STAGE NATURAL KILLER/T‐CELL LYMPHOMA: A MULTICENTRE, RANDOMISED, PHASE 3, NON‐INFERIORITY TRIAL Open
Background: Natural killer/T-cell lymphoma (NKTL) is a highly aggressive lymphoma that usually treated with intensive chemotherapy. Our phase 2 study showed that methotrexate, etoposide, dexamethasone, pegaspargase (MESA) regimen with sand…